Innovations in Retinal Disease Treatment Presentation
Clearside Biomedical, Inc. (NASDAQ: CLSD) is set to impress attendees at the 25th EURETINA Congress with notable presentations highlighting their SCS Microinjector platform. This innovative device aims to treat various retinal diseases such as diabetic macular edema and age-related macular degeneration. The event, scheduled in Paris, will feature esteemed experts discussing the efficacy of Clearside's novel delivery system.
Focus on the CLS-AX Program
Dr. Sobha Sivaprasad's Presentation
Dr. Sobha Sivaprasad will present exciting findings from the CLS-AX trial, particularly its designs for treating wet AMD and diabetic retinopathy. These trials are crucial for understanding the platform's effectiveness and the potential it holds for patients struggling with these conditions.
Key Presentations and Topics at the Congress
The Congress will feature a series of pivotal presentations that detail the advancements in the suprachoroidal space (SCS) delivery method. Participants can look forward to the following impressive topics:
- Title: Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update
- Presenter: Sobha Sivaprasad, MD, Professor of Retinal Clinical Research, Consultant Ophthalmologist
- Title: A Decade-Long Review of Suprachoroidal Drug Delivery with a Focus on Axitinib Injectable Suspension for Neovascular Age-Related Macular Degeneration
- Panel Discussion: Exploring insights from different chronic eye diseases and their management.
About Clearside's SCS Microinjector
The SCS Microinjector is lauded for its ability to deliver therapeutic agents directly into the suprachoroidal space, enhancing treatment precision. This device is set to revolutionize how therapies are administered, minimizing systemic exposure and maximizing the local effectiveness by targeting affected areas. Dr. Chong emphasizes its ability to improve patient outcomes through targeted delivery that could offer advantages over traditional treatments.
Further Innovations in Eye Care
The Future of Suprachoroidal Drug Delivery
With emerging studies supporting the safety and efficacy of suprachoroidal injections, Clearside Biomedical explores the potential benefits of their SCS platform for an array of retinal conditions. The company continues to strive towards optimizing these methods to further advance treatment options available for patients.
About Clearside Biomedical
Clearside Biomedical, Inc. is dedicated to transforming the therapeutic delivery landscape for retinal diseases. Their innovative approaches aim to enhance patient management and preserve vision for those affected by serious eye problems. With numerous programs in the pipeline, Clearside is poised to make a significant impact in ophthalmic treatments.
Frequently Asked Questions
What is the SCS Microinjector?
The SCS Microinjector is a device designed to deliver medications directly into the suprachoroidal space, allowing targeted treatment for retinal diseases.
Where and when will the EURETINA Congress take place?
The EURETINA Congress will occur in Paris, from September 4 to September 7, 2025.
Who is presenting at the Congress?
Dr. Sobha Sivaprasad and Dr. Victor Chong will be among the notable presenters discussing the advancements and findings related to the CLS-AX program.
How does the SCS delivery method benefit patients?
This method allows for targeted delivery of medications, potentially reducing systemic effects and improving efficacy in treating retinal conditions.
What diseases does Clearside's platform target?
Clearside's suprachoroidal delivery platform targets diseases such as wet AMD, diabetic retinopathy, and other ocular conditions affecting the retina.
